Trials / Completed
CompletedNCT06334731
Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
What Happened? Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (actual)
- Sponsor
- Methodist Health System · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
Detailed description
The COVID-19 pandemic accelerated/exacerbated resistance rates for key pathogens. Specifically, incidence of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBLPE), carbapenem-resistant bacteria (CRB), methicillin-resistant Staphyloccoccus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and C. difficile infections (CDI) will be higher in the pandemic time period (Pandemic, March 2020 - February 2025) compared to the pre-pandemic period (Pre-Pandemic, March 2018 - February 2020).
Conditions
Timeline
- Start date
- 2021-07-06
- Primary completion
- 2025-07-14
- Completion
- 2025-07-14
- First posted
- 2024-03-28
- Last updated
- 2025-07-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06334731. Inclusion in this directory is not an endorsement.